trust process follow-up note acq
bioprocess
dhr/ge call finish see takeaway supplement
financi detail help info bioprocess market dynam
posit pre/post acquisit link note
weve written past topic investor slide
help understand acquir asset market
thesi updat way phrase
best case scenario sharehold manag abl
acquir high growth market lead busi super
attract end market segment bioprocess alreadi
know well given pll multipl peer trade
stand-alone basi beg anoth question whether
multipl somewhat extend tool player topic
anoth day factor temper enthusiasm
modestli share quickli price
known upsid beget debat whether
re-rat higher post dental ipo/spin small new wrinkl
help w/ de-lever
solid argument valuat shift higher
asset san dental ge grow notabl faster
decreas cyclic ultim dont see one avoid
own asset next year despit today move
upsid case compel synergi
view inclus revenu cross-sel benefit
eventu interest rate also like lower
assumpt thank eu neg rate furthermor
gener increment year buy
debt rais leverag rather quickli
math roll togeth highli visibl
msd core bottom line cagrd next sever year
sign reiter outperform
everyon jazz bioprocess end market
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
live tool space last year bioprocess biopharma exposur
key growth driver space help take player core reason rapid growth
think end market grow mid-teen low point follow chart show
manufactur capac ramp next year grow
reason big capac buildout due growth biolog therapi capac need time
ge bring exist pall bioprocess workflow
rememb pall offer key product within bioprocess filtrat unit singl use
filter place junctur media/fluid ad mixtur cultur
sticki busi everyth fda approv speck
dhr posit within bioprocess workflow look like follow post-g
give sens appeal flexibl modular facil point follow schemat
outlign typic kubio facil notic variou room specif function ge/dhr product
speck closest product offer tmo/pthn space bring plenti
opportun massiv top-line synergi exist portfolio
follow quick overview ge life sci portfolio addit note call
lead global player biopharma product market
transact help reduc biolog drug product cost increas time-to-market
busi alreadi well-posit favor secular trend
runway associ biolog drug develop pipelin
prolifer cell gene therapi
busi primarili compris bioprocess expect bn revenu
upstream busi bn annual revenu core growth
lab develop system consum
downstream busi bn core growth
process chromatographi system consum
rest busi lab filtrat genom consum low-msd core growth rate
model pt updat chang far assum ye close simplic purpos
estim move higher alreadi bake thu full benefit
accret somewhat mute forecast note favor interest rate financ could add
ep time term similarli move bake modest
synergi captur note also assum ipo dental late equiti sold via
rais use ebitda assum valuat line w/ impact fairli modest help
de-lever stress test model bake upsid case could envis ep
approach stretch case pt move forward slight premium histor
impli upsid compel vs group evid market ralli
takeaway call
upstream/downstream busi ge biopharma complementari posit
filtrat
chromatographi major downstream busi except
posit mission critic product use bio-product continu evolv
innov
nearli doubl exposur biolog end market transact
repres life scienc revenu
pall transact cost save acceler innov ge
transact near term save opportun primari focu tri get busi
stand
addit top line synergi pall kubio prefabr manufactur buildout
compani assumpt core growth overal busi prudent blend growth
rate differ product categori differ growth rate
singl use technolog gene therapi dd growth rate
lab filtrat growth low-msd
year accret ep
hsd year steadili compound thereaft
credit rate post transact bbb
bn tax benefit gener deal structur relat asset vs stock
benefit probabl come first year
plan mid late part year
origin note spin/ipo omx/ ep beat guid dental spin juli
note analyst day plaza edit decemb
deeper look bioprocess growth octob
note investor day pall field edit septemb
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin februari
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
